180 related articles for article (PubMed ID: 38442309)
1. Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts.
Olesinski EA; Bhatia KS; Wang C; Pioso MS; Lin XX; Mamdouh AM; Ng SX; Sandhu V; Jasdanwala SS; Yilma B; Bohl S; Ryan JA; Malani D; Luskin MR; Kallioniemi O; Porkka K; Adamia S; Chng WJ; Osato M; Weinstock DM; Garcia JS; Letai A; Bhatt S
Blood Cancer Discov; 2024 May; 5(3):180-201. PubMed ID: 38442309
[TBL] [Abstract][Full Text] [Related]
2. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
Bhatt S; Pioso MS; Olesinski EA; Yilma B; Ryan JA; Mashaka T; Leutz B; Adamia S; Zhu H; Kuang Y; Mogili A; Louissaint A; Bohl SR; Kim AS; Mehta AK; Sanghavi S; Wang Y; Morris E; Halilovic E; Paweletz CP; Weinstock DM; Garcia JS; Letai A
Cancer Cell; 2020 Dec; 38(6):872-890.e6. PubMed ID: 33217342
[TBL] [Abstract][Full Text] [Related]
3. Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia.
Bhola PD; Mar BG; Lindsley RC; Ryan JA; Hogdal LJ; Vo TT; DeAngelo DJ; Galinsky I; Ebert BL; Letai A
J Clin Invest; 2016 Oct; 126(10):3827-3836. PubMed ID: 27599292
[TBL] [Abstract][Full Text] [Related]
4. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
[TBL] [Abstract][Full Text] [Related]
5. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
6. Dielectrophoretic Microfluidic Chip Enables Single-Cell Measurements for Multidrug Resistance in Heterogeneous Acute Myeloid Leukemia Patient Samples.
Khamenehfar A; Gandhi MK; Chen Y; Hogge DE; Li PC
Anal Chem; 2016 Jun; 88(11):5680-8. PubMed ID: 27149245
[TBL] [Abstract][Full Text] [Related]
7. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1.
Lu F; Zhang J; Ji M; Li P; Du Y; Wang H; Zang S; Ma D; Sun X; Ji C
Int J Oncol; 2014 Jul; 45(1):383-92. PubMed ID: 24756163
[TBL] [Abstract][Full Text] [Related]
8. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia.
Del Poeta G; Bruno A; Del Principe MI; Venditti A; Maurillo L; Buccisano F; Stasi R; Neri B; Luciano F; Siniscalchi A; de Fabritiis P; Amadori S
Curr Cancer Drug Targets; 2008 May; 8(3):207-22. PubMed ID: 18473734
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.
Farge T; Saland E; de Toni F; Aroua N; Hosseini M; Perry R; Bosc C; Sugita M; Stuani L; Fraisse M; Scotland S; Larrue C; Boutzen H; Féliu V; Nicolau-Travers ML; Cassant-Sourdy S; Broin N; David M; Serhan N; Sarry A; Tavitian S; Kaoma T; Vallar L; Iacovoni J; Linares LK; Montersino C; Castellano R; Griessinger E; Collette Y; Duchamp O; Barreira Y; Hirsch P; Palama T; Gales L; Delhommeau F; Garmy-Susini BH; Portais JC; Vergez F; Selak M; Danet-Desnoyers G; Carroll M; Récher C; Sarry JE
Cancer Discov; 2017 Jul; 7(7):716-735. PubMed ID: 28416471
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of mitochondrial ATPsyn-β in acute myeloid leukemia cells and with increased drug resistance.
Xiao X; Yang J; Li R; Liu S; Xu Y; Zheng W; Yi Y; Luo Y; Gong F; Peng H; Pei M; Deng M; Zhang G
PLoS One; 2013; 8(12):e83610. PubMed ID: 24391795
[TBL] [Abstract][Full Text] [Related]
11. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
12. Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia.
Tailler M; Senovilla L; Lainey E; Thépot S; Métivier D; Sébert M; Baud V; Billot K; Fenaux P; Galluzzi L; Boehrer S; Kroemer G; Kepp O
Oncogene; 2012 Jul; 31(30):3536-46. PubMed ID: 22105358
[TBL] [Abstract][Full Text] [Related]
13. Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
Garcia JS; Bhatt S; Fell G; Sperling AS; Burgess M; Keshishian H; Yilma B; Brunner A; Neuberg D; Carr SA; Ebert BL; Ballen K; Stone RM; DeAngelo DJ; Medeiros BC; Letai A
Am J Hematol; 2020 Mar; 95(3):245-250. PubMed ID: 31804723
[TBL] [Abstract][Full Text] [Related]
14. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
Lindblad O; Cordero E; Puissant A; Macaulay L; Ramos A; Kabir NN; Sun J; Vallon-Christersson J; Haraldsson K; Hemann MT; Borg Å; Levander F; Stegmaier K; Pietras K; Rönnstrand L; Kazi JU
Oncogene; 2016 Sep; 35(39):5119-31. PubMed ID: 26999641
[TBL] [Abstract][Full Text] [Related]
15. Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models.
Olesinski EA; Bhatt S
STAR Protoc; 2021 Jun; 2(2):100461. PubMed ID: 34027474
[TBL] [Abstract][Full Text] [Related]
16. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.
Vo TT; Ryan J; Carrasco R; Neuberg D; Rossi DJ; Stone RM; Deangelo DJ; Frattini MG; Letai A
Cell; 2012 Oct; 151(2):344-55. PubMed ID: 23063124
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of microRNA let-7f mediated the Adriamycin resistance in leukemia cell line.
Cao YX; Wen F; Luo ZY; Long XX; Luo C; Liao P; Li JJ
J Cell Biochem; 2020 Oct; 121(10):4022-4033. PubMed ID: 31793054
[TBL] [Abstract][Full Text] [Related]
18. Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
Glytsou C; Chen X; Zacharioudakis E; Al-Santli W; Zhou H; Nadorp B; Lee S; Lasry A; Sun Z; Papaioannou D; Cammer M; Wang K; Zal T; Zal MA; Carter BZ; Ishizawa J; Tibes R; Tsirigos A; Andreeff M; Gavathiotis E; Aifantis I
Cancer Discov; 2023 Jul; 13(7):1656-1677. PubMed ID: 37088914
[TBL] [Abstract][Full Text] [Related]
19. ABCG2 in Acute Myeloid Leukemia: Old and New Perspectives.
Damiani D; Tiribelli M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108308
[TBL] [Abstract][Full Text] [Related]
20. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway.
Yang Q; Chen K; Zhang L; Feng L; Fu G; Jiang S; Bi S; Lin C; Zhou Y; Zhao H; Chen XL; Fu G; Xu B
Cancer Lett; 2019 Oct; 461():31-43. PubMed ID: 31301319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
